Evidence map›Paper›PMID 36847938›Full record

ArticleOphthalmology and therapy2023

Psychometric Validation of the ViSIO-PRO and ViSIO-ObsRO in Retinitis Pigmentosa and Leber Congenital Amaurosis.

M Dominik Fischer, Francesco Patalano, Christel Naujoks, Judit Banhazi, Christine Bouchet, Paul O'Brien, Christine Kay, Jane Green, Todd Durham, Helena Bradley and 4 more

Open access · goldAbstract read
In one paragraph

Article in Ophthalmology and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 7 countries.

M Dominik FischerDepartment of Clinical Neurosciences, University of Oxford, Oxford, UK.
Francesco PatalanoNovartis Pharma AG, Basel, Switzerland.ORCID http://orcid.org/0000-0001-7015-6084
Christel NaujoksNovartis Pharma AG, Basel, Switzerland.ORCID http://orcid.org/0000-0002-3799-6521
Judit BanhaziNovartis Pharma AG, Basel, Switzerland.
Christine BouchetNovartis Pharma AG, Basel, Switzerland.ORCID http://orcid.org/0000-0002-9737-1179
Paul O'BrienNovartis Ireland Ltd, Dublin, Ireland.ORCID http://orcid.org/0000-0002-6064-8023
Christine KayVitreoretinal Associates, Gainesville, FL, USA.
Jane GreenDiscipline of Genetics, Faculty of Medicine, Memorial University of Newfoundland, Craig L Dobbin Genetics Research Centre, St. John's, Canada.
Todd DurhamFoundation Fighting Blindness, Columbia, MD, USA.ORCID http://orcid.org/0000-0002-0363-0329
Helena BradleyAdelphi Values Ltd, Bollington, Cheshire, UK. helena.bradley@adelphivalues.com.ORCID http://orcid.org/0000-0002-7077-2183
Nicola WilliamsonAdelphi Values Ltd, Bollington, Cheshire, UK.
Melissa BarclayAdelphi Values Ltd, Bollington, Cheshire, UK.
Joel SimsAdelphi Values Ltd, Bollington, Cheshire, UK.ORCID http://orcid.org/0000-0003-0474-2186
Isabelle AudoInstitut de la Vision, CHNO des Quinze-Vingts, National Rare Disease Center REFERET and INSERM-DGOS CIC 1423, Sorbonne Université, INSERM, CNRS, 75012, Paris, France.
Adelphi Group (United Kingdom) · GBNovartis (Switzerland) · CHCentre National de la Recherche Scientifique · FRFoundation Fighting Blindness · USMemorial University of Newfoundland · CANovartis (Ireland) · IERetina Vitreous Associates of Florida · USUniversity of Oxford · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRetinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA) are rare inherited retinal degenerative disorders. The Visual Symptom and Impact Outcomes patient-reported outcome (ViSIO-PRO) and observer-reported outcome (ViSIO-ObsRO) instruments were developed in this population to assess visual function symptoms and impacts on vision-dependent activities of daily living (ADL) and distal health-related quality of life (HRQoL). This study aimed to explore the psychometric properties of the ViSIO-PRO and ViSIO-ObsRO in RP/LCA.

methodsThe 49-item ViSIO-PRO and 27-item ViSIO-ObsRO instruments were completed by 83 adult and adolescent patients and 22 caregivers of child patients aged 3-11 years with RP/LCA, respectively, at baseline and 12-16-day follow-up. Concurrent measures were also administered at baseline. Psychometric analyses assessed item (question) properties, dimensionality, scoring, reliability, validity, and score interpretation.

resultsItem responses were mainly evenly distributed across the response scale, and inter-item correlations were mostly moderate to strong (> 0.30) at baseline within hypothesized domains. Item deletion was informed by item properties, qualitative data, and clinical input and supported retention of 35 ViSIO-PRO items and 25 ViSIO-ObsRO items. Confirmatory factor analysis in line with pre-hypothesized domains supported a four-factor model assessing visual function symptoms, mobility, vision-dependent ADL, and distal HRQoL. A bifactor model supported calculation of total scores and four domain scores. Internal consistency was high for domain and total scores (Cronbach's alpha > 0.70) and test-retest reliability for total scores was strong between baseline and 12-16-day follow-up (intraclass correlation coefficients 0.66-0.98). Convergent validity was supported by strong correlations in a logical pattern with concurrent measures. Mean baseline scores differed significantly between severity groups. Distribution-based methods provided initial insights to guide interpretation of scores.

conclusionsFindings supported item reduction and established scoring of the instruments. Evidence of reliability and validity as outcome measures in RP/LCA was also reported. Further research is ongoing to explore responsiveness of the ViSIO-PRO and ViSIO-ObsRO instruments and interpretation of change scores.

Indexed as

Clinical outcome assessmentInherited retinal diseaseLeber congenital amaurosisObserver-reported outcomePatient-reported outcomePsychometricsRetinitis pigmentosa

Identifiers

PMID36847938
PMCPMC10011359
OpenAlexW4322494095

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.